- COVID-19 Vaccine Frontrunners: Four vaccine candidates—two in the US, one in China, and one in the UK—have been approved for early testing in people. Several others are close on their heels. https://www.the-scientist.com/news-opinion/covid-19-vaccine-frontrunners-67382 3 comments europe
Linking pages
Linked pages
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial - The Lancet https://www.thelancet.com/journals/lancet/article/piis0140-6736(20)31604-4/fulltext 2846 comments
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext 2572 comments
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2022483 1299 comments
- Covid: Pfizer and AstraZeneca jabs work against Indian variant - study - BBC News https://www.bbc.com/news/uk-57214596 978 comments
- https://www.nejm.org/doi/pdf/10.1056/NEJMoa2101765?articleTools=true 528 comments
- Covid-19: EU states to resume AstraZeneca vaccine rollout - BBC News https://www.bbc.co.uk/news/world-europe-56440139 372 comments
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia - The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext 144 comments
- Disappointing Chinese Vaccine Results Pose Setback for Developing World - The New York Times https://www.nytimes.com/2021/01/13/business/chinese-vaccine-brazil-sinovac.html 65 comments
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine | NEJM https://www.nejm.org/doi/full/10.1056/nejmoa2026920 63 comments
- Cuba says Abdala vaccine 92.28% effective against coronavirus | Reuters https://www.reuters.com/business/healthcare-pharmaceuticals/cuba-says-abdala-vaccine-9228-effective-against-coronavirus-2021-06-21/ 60 comments
- https://www.researchgate.net/publication/341354165_MMR_Vaccine_Appears_to_Confer_Strong_Protection_from_COVID-19_Few_Deaths_from_SARS-CoV-2_in_Highly_Vaccinated_Populations 52 comments
- Canada pauses AstraZeneca vaccine for under 55 | AP News https://apnews.com/article/canada-panel-astrazeneca-vaccine-pause-under-55-06dde56d2db78d72c5bb9bcb97be4d5a 27 comments
- Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use | Johnson & Johnson https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial 23 comments
- Statement by NSC Spokesperson Emily Horne on National Security Advisor Jake Sullivan’s Call with National Security Advisor Ajit Doval of India - The White House https://www.whitehouse.gov/briefing-room/statements-releases/2021/04/25/statement-by-nsc-spokesperson-emily-horne-on-national-security-advisor-jake-sullivans-call-with-national-security-advisor-ajit-doval-of-india/ 23 comments
- Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia - The Lancet https://www.thelancet.com/journals/lancet/article/piis0140-6736(20)31866-3/fulltext 15 comments
- Variant Found in Brazil Could Evade Immunity from Past Infection | The Scientist Magazine® https://www.the-scientist.com/news-opinion/variant-found-in-brazil-could-evade-immunity-from-past-infection-68506 10 comments
- Vaxart Announces Selection of its Oral COVID-19 Vaccine https://www.globenewswire.com/news-release/2020/05/20/2036357/0/en/Vaxart-Announces-Selection-of-its-Oral-COVID-19-Vaccine-Lead-Candidate.html 8 comments
- A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity | Nature https://www.nature.com/articles/s41586-020-2599-8 4 comments
- https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study 3 comments
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2034577 1 comment
Related searches:
Search whole site: site:the-scientist.com
Search title: Track COVID-19 Vaccines Advancing Through Clinical Trials | The Scientist Magazine®
See how to search.